Skip to main
  1. Stocks
  2. Fate Therapeutics
  3. Forecast
FATE

Fate Therapeutics (FATE) Stock Forecast & Price Target

Fate Therapeutics (FATE) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Fate Therapeutics is viewed favorably because FT819 is showing favorable safety, with lower AESI rates and no ICANS or IEC-HS, while early efficacy in lupus nephritis includes 2/2 renal responses after bendamustine conditioning and durable benefit beyond 6 months. The company’s outpatient administration and use in community hospitals suggest a more accessible commercial profile than TCEs or autologous cell therapies, and the registrational Phase II RECLAIM-LN study in 53 patients with a 6-month CRR endpoint provides a clear catalyst path. Beyond FT819, IND clearance for FT839 and early antitumor activity for FT836 broaden the pipeline, supporting a higher projected enterprise value of $1.09 billion versus $766 million.

Bears say

Fate Therapeutics is exposed to substantial fundamental risk because its iPSC-derived NK and T-cell candidates could fail clinically, run into regulatory setbacks, or prove commercially unviable. The autoimmune disease market is highly competitive, and stronger-than-expected competitor dynamics could erode any potential advantage while a more unfavorable political and commercial environment could further weaken adoption prospects. In addition, the company will likely require additional cash and may face future litigation, which raises financing and execution risk on top of already uncertain development outcomes.

Fate Therapeutics (FATE) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fate Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Fate Therapeutics (FATE) Analyst Forecast & Price Prediction

Get the latest Fate Therapeutics (FATE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Fate Therapeutics (FATE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fate Therapeutics (FATE) Forecast

Analysts have given Fate Therapeutics (FATE) a Buy based on their latest research and market trends.

According to 4 analysts, Fate Therapeutics (FATE) has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fate Therapeutics (FATE)


Fate Therapeutics (FATE) Analyst Forecast & Price Prediction

Get the latest Fate Therapeutics (FATE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Fate Therapeutics (FATE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover FATE stock data and trends